1. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8.Arch Ophthalmol 2001;119 (10) 1417- 1436
  2. AnastasopoulosE, Yu F, Coleman AL. Age-related macular degeneration is associated with an increased risk of hip fractures in the Medicare database. American journal of ophthalmology. 2006;142(6): 1081-1083.
  3. AndermannA, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years: Bulletin of the World Health Organization; 2008 Volume 86, Number 4, April 2008, 241-320 Accessed 26 October 2017.
  4. BlackJR, Clark SJ. Age-related macular degeneration: genome-wide association studies to translation. Genetics in medicine: official journal of the American College of Medical Genetics. 2016;18(4): 283-289.
  5. BoyerDS, Schmidt-Erfurth U, van Lookeren Campagne M, Henry EC, Brittain C. The Pathophysiology of Geographic Atrophy Secondary to Age-Related Macular Degeneration and the Complement Pathway as a Therapeutic Target. Retina. 2017;37(5): 819-835.
  6. BrodyBL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108(10): 1893-1900; discussion 1900-1891.
  7. BrownDM, Kaiser PK, Michels M, et al. ANCHOR Study Group, Ranibizumab versus verteporfin for neovascular age-related macular degeneration.N Engl J Med 2006;355 (14) 1432- 1444PubMed
  8. BrownMM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR. Age-related macular degeneration: economic burden and value-based medicine analysis. Canadian journal of ophthalmology Journal canadien d’ophtalmologie. 2005;40(3): 277-287.
  9. CATT Research Group. Five-year outcomes with anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. May 2, 2016. DOI: 10.1016/j.ophtha.2016.03.045
  10. ColijnJM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et al. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology. 2017.
  11. Deloitte Access Economics 2011. The economic impact of vision impairment and blindness in the Republic of Ireland. National Council for the Blind of Ireland. Available at: Accessed August 7 2017
  12. FerrisFL, 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120(4): 844-851.
  13. FlaxmanSR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017 Oct 10. pii: S2214-109X(17)30393-5.
  14. FleckensteinM, Schmitz-Valckenberg S, Adrion C, Visvalingam S, Gobel AP, Mossner A, et al. Progression of age-related geographic atrophy: role of the fellow eye. Investigative ophthalmology & visual science. 2011;52(9): 6552-6557.
  15. FritscheLG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nature genetics. 2016;48(2): 134-143.
  16. GopinathB, Craig A, Kifley A, Liew G, Bloffwitch J, Vu KV, et al. Implementing a multi-modal support service model for the family caregivers of persons with age-related macular degeneration: a study protocol for a randomised controlled trial. BMJ open. 2017;7(8): e018204.
  17. GopinathB, Kifley A, Cummins R, Heraghty J, Mitchell P. Predictors of psychological distress in caregivers of older persons with wet age-related macular degeneration. Aging & mental health. 2015;19(3): 239-246.
  18. GrassmannF, Fleckenstein M, Chew EY, Strunz T, Schmitz-Valckenberg S, Gobel AP, et al. Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration. PloS one. 2015;10(5): e0126636.
  19. GrobS, Luo J, Hughes G, Lee C, Zhou X, Lee J, et al. Genetic analysis of simultaneous geographic atrophy and choroidal neovascularization. Eye. 2012;26(8): 1106-1113.
  20. GrunwaldJE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF, Comparison of Age-related Macular Degeneration Treatments Trials Research G. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(4): 809-816.
  21. HassellJB, Lamoureux EL, Keeffe JE. Impact of age related macular degeneration on quality of life. The British journal of ophthalmology. 2006;90(5): 593-596.
  22. HolzFG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121(5): 1079-1091.
  23. IAPB Vision Atlas Accessed October 2017.
  24. JoachimN, Mitchell P, Kifley A, Rochtchina E, Hong T, Wang JJ. Incidence and progression of geographic atrophy: observations from a population-based cohort. Ophthalmology. 2013;120(10): 2042-2050.
  25. KaszubskiP, Ben Ami T, Saade C, Smith RT. Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review. Ophthalmic research. 2016;55(4): 185-193.
  26. KimelM, Leidy NK, Tschosik E, Dolan C, Souied EH, Varma R, Bressler NM. Functional Reading Independence (FRI) Index: A New Patient-Reported Outcome Measure for Patients With Geographic Atrophy. Investigative ophthalmology & visual science. 2016;57(14): 6298-6304.
  27. LamoureuxEL, Pallant JF, Pesudovs K, Rees G, Hassell JB, Keeffe JE. The effectiveness of low-vision rehabilitation on participation in daily living and quality of life. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1476-82.
  28. MangioneCM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25)(2001). Archives of Ophthalmology. 119, 1050-1058
  29. MoshfeghiAA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113 (11) 2002.e1- 2002.e12
  30. OwenCG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. The British journal of ophthalmology. 2012;96(5): 752-756.
  31. PrennerJL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R. Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study. American journal of ophthalmology. 2015;160(4): 725-731 e721.
  32. ReinDB, Wittenborn JS et al. Forecasting Age-related Macular Degeneration through the year 2050. The potential impact of new treatments. Arch Ophthalmol 2009;127:533-540
  33. RovnerBW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. Archives of ophthalmology. 2002;120(8): 1041-1044.
  34. RudnickaAR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. 2012;119(3): 571-580.
  35. RudnickaAR, Kapetanakis VV, Jarrar Z, Wathern AK, Wormald R, Fletcher AE, et al. Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis. American journal of ophthalmology. 2015;160(1): 85-93 e83.
  36. SaddaSR, Chakravarthy U, Birch DG, Staurenghi G, Henry EC, Brittain C. Clinical Endpoints for the Study of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Retina. 2016;36(10): 1806-1822
  37. SardellRJ, Persad PJ, Pan SS, Whitehead P, Adams LD, Laux RA, et al. Progression Rate From Intermediate to Advanced Age-Related Macular Degeneration Is Correlated With the Number of Risk Alleles at the CFH Locus. Investigative ophthalmology & visual science. 2016;57(14): 6107-6115.
  38. SchmierJK, Jones ML, Halpern MT. The burden of age-related macular degeneration. PharmacoEconomics. 2006;24(4): 319-334.
  39. Schmitz-ValckenbergS, Sahel JA, Danis R, Fleckenstein M, Jaffe GJ, Wolf S, et al. Natural History of Geographic Atrophy Progression Secondary to Age-Related Macular Degeneration (Geographic Atrophy Progression Study). Ophthalmology. 2016;123(2): 361-368.
  40. Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, et al. Guidelines for accurate and transparent health estimates reporting: The GATHER statement. Lancet. 2016.
  41. Stevenson MR, Hart PM, Montgomery AM, McCulloch DW, Chakravarthy U. Reduced vision in older adults with age related macular degeneration interferes with ability to care for self and impairs role as carer. The British journal of ophthalmology. 2004;88(9): 1125-1130.
  42. SunnessJS, Margalit E, Srikumaran D, Applegate CA, Tian Y, Perry D, et al. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology. 2007;114(2): 271-277.
  43. SunnessJS, Rubin GS, Applegate CA, Bressler NM, Marsh MJ, Hawkins BS, Haselwood D. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. Ophthalmology. 1997;104(10): 1677-1691.
  44. Sunness JS, Rubin GS, Zuckerbrod A, Applegate CA. Foveal-Sparing Scotomas in Advanced Dry Age-Related Macular Degeneration. Journal of visual impairment & blindness. 2008;102(10): 600-610.
  45. Sunness The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration. Molecular vision. 1999;5: 25.
  46. SzaboSM, Janssen PA, Khan K, Potter MJ, Lord SR. Older women with age-related macular degeneration have a greater risk of falls: a physiological profile assessment study. Journal of the American Geriatrics Society. 2008;56(5): 800-807.
  47. Takeda AL, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 2007;91 (9) 1177- 1182
  48. TamuraH, Goto R, et al. The clinical effectiveness and cost effectiveness of screening for age-related macular degeneration in Japan: a Markov modelling study. PLOS One 2015;10(7):e0133628.doi:10.1371/ journal.pone.0133628
  49. TaylorDJ, Edwards LA, Binns AM & Crabb DP. Seeing it differently: self-reported description of vision loss in dry age-related macular degeneration. Ophthalmic Physiol Opt 2017.
  50. TaylorDJ, Hobby AE, Binns AM, Crabb DP. How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ open. 2016;6(12): e011504.
  51. United Nations, Department of Economic and Social Affairs, Population Division (2015), World Population Prospects: The 2015 revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP.241.
  52. VukicevicM, Heraghty J, Cummins R, Gopinath B, Mitchell P. Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration. Eye. 2016;30(3): 413-421.
  53. WilsonJMG; Jungner G (1968). “Principles and practice of screening for disease” (PDF). WHO Chronicle. Geneva: World Health Organization. 22 (11): 473 Public Health Papers, #34
  54. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global health. 2014;2(2): e106-116.
  55. WoodJM, Lacherez P, Black AA, Cole MH, Boon MY, Kerr GK. Risk of falls, injurious falls, and other injuries resulting from visual impairment among older adults with age-related macular degeneration. Investigative ophthalmology & visual science. 2011;52(8): 5088-5092.


Newsletter Signup

To keep up to date with our news and activities,
please leave your details below

GDPR Compliance Please indicate your consent for Retina International to contact you via the email address listed for the purposes of general alerts and newsletters.